Medicare Enrolled

Dr. Paul Richardson, MD

Hematology & Oncology · Boston, MA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
44 BINNEY STREET, Boston, MA 02115
6176322104
In practice since 2006 (20 years)
NPI: 1770544256 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Richardson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Richardson? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Richardson

Dr. Paul Richardson is a hematology & oncology specialist in Boston, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Richardson performed 428 Medicare services across 302 unique beneficiaries.

Between the years covered by Open Payments, Dr. Richardson received a total of $576,583 from 31 pharmaceutical and/or device companies across 279 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Richardson is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ 428 Medicare services $576,583 industry payments

Medicare Practice Summary

Medicare Utilization ↗
428
Medicare services
Bottom 49% in MA for hematology & oncology
302
Unique beneficiaries
$119
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~21 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
 375 $119 $728
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 29 $83 $410
New patient office visit, complex (60-74 min) 24 $151 $880
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$576,583
Total received (2018-2024)
Avg $82,369/year across 7 years
Top 1% in MA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
279
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$358,852 (62.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$135,125 (23.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$82,605 (14.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$29,360
2023
$37,928
2022
$63,914
2021
$112,574
2020
$97,473
2019
$105,471
2018
$129,863

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$18,771
GlaxoSmithKline, LLC.
$9,040
E.R. Squibb & Sons, L.L.C.
$1,229
BioLineRx USA, Inc.
$171
Celgene Corporation
$123
Legend Biotech USA Inc.
$26
Top 3 companies account for 98.9% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$116,066
GENZYME CORPORATION
$86,034
Jazz Pharmaceuticals Inc.
$42,000
Takeda Pharmaceuticals U.S.A., Inc.
$40,868
Takeda Pharmaceutical Company, Limited
$38,625
Janssen Global Services, LLC
$32,005
GlaxoSmithKline, LLC.
$31,753
Karyopharm Therapeutics Inc.
$28,456
Regeneron Pharmaceuticals, Inc.
$21,132
E.R. Squibb & Sons, L.L.C.
$19,002
Secura Bio, Inc.
$18,830
JAZZ PHARMACEUTICALS INC.
$18,709
SANOFI-AVENTIS U.S. LLC
$15,500
Amgen Inc.
$15,073
SECURA BIO, INC.
$12,500
Adaptive Biotechnologies Corporation
$8,416
Novartis Pharmaceuticals Corporation
$8,170
AstraZeneca UK Limited
$6,613
AbbVie Inc.
$4,306
PFIZER INC.
$3,375
AstraZeneca Pharmaceuticals LP
$2,800
Gilead Sciences, Inc.
$2,150
Epizyme, Inc.,
$1,500
Incyte Corporation
$1,230
Janssen Biotech, Inc.
$923
BioLineRx USA, Inc.
$171
MENARINI SILICON BIOSYSTEMS, INC.
$148
Janssen Scientific Affairs, LLC
$148
AbbVie, Inc.
$29
Stemline Therapeutics Inc.
$26
Legend Biotech USA Inc.
$26
Top 3 companies account for 42.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · APHEXDA · CC-92480 · CD38 · COPIKTRA · Cellsearch · DARZALEX · DEFITELIO · Defitelio · ELZONRIS · EMPLICITI · FARYDAK · Farydak · IMBRUVICA · ISATUXIMAB · Kyprolis · LIBTAYO · NINLARO · NO PRODUCT DISCUSSED · Nplate · Pomalyst · Revlimid · SARCLISA · TAZVERIK · TECVAYLI · XPOVIO · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (62%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for hematology & oncology in MA.

Looking for a hematology & oncology specialist in Boston?
Compare hematology & oncology specialists in the Boston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
269
Per 100K population
34.4
County median income
$92,859
Nearest hospital
BRIGHAM AND WOMEN'S HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Richardson is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 1% of MA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Richardson experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Richardson performed 375 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Richardson receive payments from pharmaceutical companies?
Yes. Dr. Richardson received a total of $576,583 from 31 companies across 279 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Richardson's costs compare to other hematology & oncology specialists in Boston?
Dr. Richardson's average Medicare payment per service is $119. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Richardson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Hematology & Oncology Specialists in Boston
Browse hematology & oncology specialists in Boston ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MA
Which MA hematology & oncology specialists receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Jazz Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Jazz Pharmaceuticals Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →